- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lineage Cell Therapeutics Inc (LCTX)
Fair Value
An estimate of a Lineage Cell Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.170
1.240
52 wk Range
0.365
1.310
LCTX Financial Summary
A brief financial summary of Lineage Cell Therapeutics Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.
Key Ratios
Statements Highlights
| Period Ending: | 2015 31/12 | 2016 31/12 | 2017 31/12 | 2018 31/12 | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1.83 | 4.34 | 14.7 | 8.95 | 9.5 | |
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1.44 | 2.92 | 13.98 | -7.43 | -3.31 | |
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -26.45 | -49.21 | -22.52 | -21.2 | -21.48 | |
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -20.65 | -43.02 | -26.27 | -21.49 | -18.61 | |
Total Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 107.95 | 174.55 | 123.66 | 101.02 | 113.22 | |
Total Current Liabilities | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 7.77 | 47.12 | 18.98 | 17.96 | 13.98 | |
Total Equity | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 95.13 | 90.9 | 71.94 | 62.02 | 77.01 | |
Levered Free Cash Flow | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 13.44 | -37.46 | 13.34 | -10.37 | -12.8 | |
Cash from Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -19.75 | -23.56 | 1.06 | -28.57 | -23.09 | |
Cash from Investing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 13.04 | 9.75 | -46.16 | 46.45 | -2.31 | |
Cash from Financing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 29.87 | 36.93 | 1.63 | 6.42 | 35.86 | |
Net Change in Cash | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 23.09 | 23.09 | -44.34 | 24.06 | 10.36 | |
* In Millions of USD (except for per share items)
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.167
(+247.22% Upside)
FAQ
What were Lineage Cell Therapeutics's earnings for the latest quarter?
The Lineage Cell Therapeutics EPS (TTM) is -0.19. Lineage Cell Therapeutics reported sales of 2.77, net income of -30.46, and EPS of -0.13 for the latest quarter.
What was Lineage Cell Therapeutics's net income for the latest quarter?
Lineage Cell Therapeutics's net income for the latest quarter was -30.46.
How did Lineage Cell Therapeutics's performance compare year-over-year in the latest quarter?
The company's revenue moved from 1.50 in the previous quarter to 2.77 in the latest quarter, and net income moved from -4.14 to -30.46 compared to the previous quarter.
What is Lineage Cell Therapeutics's net profit margin on a TTM basis?
Lineage Cell Therapeutics's trailing twelve months (TTM) net profit margin is -195.90%.
How does Lineage Cell Therapeutics's debt to equity ratio compare to industry standards?
Lineage Cell Therapeutics's total debt-to-equity ratio is 4.57%.
What is Lineage Cell Therapeutics's return on investment on a TTM basis?
Lineage Cell Therapeutics's trailing twelve months (TTM) return on investment (ROI) is -71.51%.
Did Lineage Cell Therapeutics gain or lose cash last quarter?
In the latest quarter, Lineage Cell Therapeutics's net change in cash was -5.57 million.
What were Lineage Cell Therapeutics's total assets and liabilities in the latest quarter?
As of the latest quarter, Lineage Cell Therapeutics reported total assets of 90.80 million and total liabilities of 10.76 million.
How has Lineage Cell Therapeutics's total revenue grown this year?
Lineage Cell Therapeutics's total revenue was 1.50 in the previous quarter and 2.77 in the latest quarter.
What is Lineage Cell Therapeutics's gross margin on a TTM basis?
Lineage Cell Therapeutics's trailing twelve months (TTM) gross margin is -19.86%.
What was Lineage Cell Therapeutics's revenue per share for the latest quarter?
Lineage Cell Therapeutics's revenue per share for the latest quarter was 3.08.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.